Human T-cell leukemia virus type I-associated myelopathy following living-donor liver transplantation

TitleHuman T-cell leukemia virus type I-associated myelopathy following living-donor liver transplantation
Publication TypeJournal Article
Year of Publication2008
AuthorsSoyama A, Eguchi S, Takatsuki M, Ichikawa T, Moriuchi M, Moriuchi H, Nakamura T, Tajima Y, Kanematsu T
JournalLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
Pagination647 - 50
Date PublishedMay
Type of ArticleCase Reports
ISSN1527-6473 (Electronic) 1527-6465 (Linking)
Accession Number18433046
Keywords*Living Donors, Antiviral Agents / therapeutic use, Drug Therapy, Combination, Gait Disorders, Neurologic / etiology, Graft Rejection / prevention & control, Hepatitis C / *complications / surgery, Humans, Immunosuppressive Agents / therapeutic use, Interferon Alfa-2b / therapeutic use, Liver Cirrhosis / *surgery / virology, Liver Transplantation / *adverse effects, Male, Middle Aged, Paraparesis, Tropical Spastic / complications / drug therapy / *etiology, Steroids / therapeutic use, Tacrolimus / therapeutic use, Treatment Outcome, Urination Disorders / etiology

This report describes a patient who developed human T-cell leukemia virus type I-associated myelopathy (HAM) following a living-donor liver transplantation (LDLT) for liver cirrhosis due to hepatitis C virus (HCV) infection. Both the recipient and the living donor (his sister) were human T-cell leukemia virus type I (HTLV-I) carriers. Since the LDLT, he had been treated with immunosuppressive drugs such as tacrolimus and steroids as well as interferon-alpha to prevent rejection and a recurrence of the HCV infection, respectively. Even though the HTLV-I proviral load had decreased upon interferon treatment, he developed a slowly progressive gait disturbance with urinary disturbance 2 years after the LDLT and was diagnosed with HAM. This appears to be the first report of HAM development in an HLTV-I-infected LDLT recipient.

Alternate JournalLiver Transpl
Notify Library Reference ID1429

Related Incidents